New approved dasatinib regimen available for clinical use

References

• Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med.145(12), 913–923 (2006).
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood108(6), 1809–1820 (2006).
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.348(11), 994–1004 (2003).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355(23), 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP et al.In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res.65(11), 4500–4505 (2005).
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res.66, 5790–5797 (2006).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood109(6), 2303–2309 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood109(12), 5143–5150 (2007).
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood109(10), 4143–4150 (2007).
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood109(8), 3207–3213 (2007).
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Baccarani M et al. Dasatinib induces rapid hematologic and cytogenetic responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood110(7), 2309–2315 (2007).
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol.26(19), 3204–3412 (2008).
   PubMed Web of Science ®Google Scholar
• Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J. Hematol. Oncol.1, 15 (2008).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood102(1), 276–283 (2003).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med.354(24), 2531–2541 (2006).
   PubMed Web of Science ®Google Scholar
• ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood84(6), 1731–1736 (1994).
   PubMed Web of Science ®Google Scholar
• Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem.269(37), 22925–22928 (1994).
   PubMed Web of Science ®Google Scholar
• Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood84(9), 2912–2918 (1994).
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Baccarani M, Cervantes F et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J. Clin. Oncol.26(Suppl.), 7009a (2008).
   Google Scholar
• Rousselot PH, Facon T, Paquette R, Bleickardt E, Dejardin D, Kantarjian HM. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R. J. Clin. Oncol.26(Suppl.), 7012a (2008).
   Google Scholar
• Shah NP, Nicoll JM, Bleickardt E, Nicaise C, Paquette RL, Sawyers CL. Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development. Blood108(Suppl.), 2166a (2006).
   Google Scholar
• Wang X, Hochhaus A, Kantarjian HM et al. Dasatinib pharmacokinetics and exposure–response (E–R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J. Clin. Oncol.26(Suppl.), 3590a (2008).
   PubMedGoogle Scholar
• Porkka K, Martinelli G, Ottmann O et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Haematologica93(Suppl.), 1 (2008) (Abstract 0001).
   PubMedGoogle Scholar
• Rea D, Dombret H, Kim DW et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A. Haematologica93(Suppl.), 391 (2008) (Abstract 0982).
   Google Scholar
• Saglio G, Dombret H, Rea D et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. Haematologica93(Suppl.), 349 (2008) (Abstract 0880).
   Google Scholar
• Larson RA, Druker BJ, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS Study. Blood111, 4022–4028 (2008).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, O’Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood101(2), 473–475 (2003).
   PubMed Web of Science ®Google Scholar
• Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin. Cancer Res.9(6), 2092–2097 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood110(10), 3540–3546 (2007).
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Goldberg SL, Mauro M et al. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. Haematologica93(Suppl.), 51 (2008) (Abstract 0128).
   Google Scholar
• Khoury HJ. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 7015).
   PubMedGoogle Scholar
• Rosti G, Hochhaus A, le Coutre P et al. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant Philadelphia-positive chronic myelogenous leukemia in either chronic phase or accelerated phase. Haematologica92(Suppl.), 319 (2007) (Abstract 0860).
   Google Scholar
• Cortes J, Jabbour E, Hochhaus A et al. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant Philadelphia-positive (Ph+) chronic myelogenous leukemia (CML) in either chronic phase (CP) or accelerated phase (AP). Blood110(Suppl.), 1040a (2007).
   Google Scholar
• Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood102(7), 2702–2703 (2003).
   PubMed Web of Science ®Google Scholar
• Cortes JG, Baccarani M, Guilhot F et al. First report of the TOPS study: a randomized Phase III trial of 400mg vs 800mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints. Haematologica93(Suppl.), 160 (2008) (Abstract 0402).
   Google Scholar
• Hughes T, Saglio G, Martinelli G et al. Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. Blood110(11), 320a (2007).
   Web of Science ®Google Scholar
• Mueller M, Branford S, Radich J et al. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. J. Clin. Oncol.25(18S), 7024a (2007).
   Google Scholar
• Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood99(9), 3472–3475 (2002).
   PubMed Web of Science ®Google Scholar